Physician profile
Nasser Janbay
NPI 1699768374
$690.83
in general payments reported to CMS, 2019-2025
12 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $143 · 2021: $38.01 · 2022: $170 · 2023: $57.27 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198 · Education: $37.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.88 |
| Education | $37.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $200.87 | 2022-2023 | |
| Janssen Biotech, INC. | $118.07 | 2020 | |
| Amgen INC. | $102.63 | 2025 | Imdelltra (Amg757) |
| Tempus Ai, INC | $75.78 | 2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $56.44 | 2019 | |
| Merck Sharp & Dohme LLC | $26.26 | 2019-2020 | |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Abbvie INC. | $20.43 | 2019 | |
| Eisai INC. | $14.17 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.08 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasser Janbay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.